Neoadjuvant Chemohormonal Therapy in Poor-Prognosis Localized Prostate Cancer

Keyphrases

• Poor Prognosis 100%
• Prostate-specific Antigen 100%
• Localized Prostate Cancer 100%
• Neoadjuvant Endocrine Therapy 100%
• Radical Prostatectomy 66%
• Nerve Preservation 66%
• High Risk 33%
• In(III) 33%
• Patient Characteristics 33%
• Pathologic 33%
• 4-cycle 33%
• Blockage 33%
• Radiotherapy 33%
• Prostate Cancer 33%
• Systemic Therapy 33%
• Median Range 33%
• Capsular 33%
• Neoadjuvant 33%
• Androgens 33%
• Docetaxel 33%
• Gleason Score 33%
• Estramustine 33%
• Chemohormonal Therapy 33%
• Organ-confined Disease 33%
• Prostate-specific Antigen Doubling Time 33%
• Seminal Vesicle 33%
• Chemohormonal 33%
• Local Relapse 33%
• Relapsed Patients 33%
• Gleason Sum 33%
• Tumor Downstaging 33%
• Lymph Node Involvement 33%
• Systemic Relapse 33%
• Local Therapy 33%
• Preservation Surgery 33%
• Relapse Pattern 33%

Medicine and Dentistry

• Prostate Cancer 100%
• Prostate Specific Antigen 100%
• Disease 75%
• Clinical Stage 75%
• Prostatectomy 50%
• Gleason Score 50%
• Neoplasm 25%
• Radiation Therapy 25%
• Lymph Node 25%
• Patient Characteristics 25%
• Androgen 25%
• Local Therapy 25%
• Systemic Therapy 25%
• Docetaxel 25%
• Estramustine 25%
• Seminal Vesicle Disease 25%

Immunology and Microbiology

• Prostate Specific Antigen 100%
• Gleason Score 50%
• Lymph Node 25%
• Seminal Vesicle 25%